Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Renal Cell 30Neoplasms 11Sarcoma 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 7Ovarian Neoplasms 6Neoplasm Metastasis 5Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Recurrence 2Hemangiosarcoma 2Financial Stress 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Ovarian Epithelial 2Uterine Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Diseases 1Solid Tumours 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Prostatic Neoplasms 1Patient Preference 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Plasma Cell 1Melanoma 1Liver Neoplasms 1Leiomyosarcoma 1

Interventions

pembrolizumab 2Lapatinib 2pertuzumab 1pazopanib 1bemcentinib 1Trastuzumab 1Surgical Procedures, Operative 1Radiotherapy 1Injections, Subcutaneous 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Inflammatory Breast Neoplasms × pazopanib × Clear all
NCT00558103 2013-02-04

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

GlaxoSmithKline

Phase 2 Completed
163 enrolled 14 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡